Citations (156)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (22)
Xingmei Yao, Wengang He, Xianghong Wu, Jianxiang Gu, Jing Zhang, Bizhen Lin, Zhaofeng Bi, Yingying Su, Shoujie Huang, Yuemei Hu, Ting Wu, Jun Zhang & Ningshao Xia. (2022) Long-Term immunopersistence and safety of the Escherichia coli-produced HPV-16/18 bivalent vaccine in Chinese adolescent girls. Human Vaccines & Immunotherapeutics 18:5.
Read now
Read now
Chun-Lan Zhuang, Zhi-Jie Lin, Zhao-Feng Bi, Ling-Xian Qiu, Fang-Fang Hu, Xiao-Hui Liu, Bi-Zhen Lin, Ying-Ying Su, Hui-Rong Pan, Tian-Ying Zhang, Shou-Jie Huang, Yue-Mei Hu, You-Lin Qiao, Feng-Cai Zhu, Ting Wu, Jun Zhang & Ning-Shao Xia. (2021) Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response. Emerging Microbes & Infections 10:1, pages 365-375.
Read now
Read now
Nathalie Garçon & Alberta Di Pasquale. (2017) From discovery to licensure, the Adjuvant System story. Human Vaccines & Immunotherapeutics 13:1, pages 19-33.
Read now
Read now
Taylor B. Turner & Warner K. Huh. (2016) HPV vaccines: Translating immunogenicity into efficacy. Human Vaccines & Immunotherapeutics 12:6, pages 1403-1405.
Read now
Read now
S. Rachel Skinner, Dan Apter, Newton De Carvalho, Diane M. Harper, Ryo Konno, Jorma Paavonen, Barbara Romanowski, Cecilia Roteli-Martins, Nansa Burlet, Attila Mihalyi & Frank Struyf. (2016) Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases. Expert Review of Vaccines 15:3, pages 367-387.
Read now
Read now
Sabrina E Vinzón & Frank Rösl. (2015) HPV vaccination for prevention of skin cancer. Human Vaccines & Immunotherapeutics 11:2, pages 353-357.
Read now
Read now
Sandra D Isidean, Joseph E Tota, Julien A Gagnon & Eduardo L Franco. (2015) Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs. Expert Review of Vaccines 14:1, pages 119-133.
Read now
Read now
Rosa De Vincenzo, Carmine Conte, Caterina Ricci, Giovanni Scambia & Giovanni Capelli. (2014) Long-term efficacy and safety of human papillomavirus vaccination. International Journal of Women's Health 6, pages 999-1010.
Read now
Read now
Mark H Einstein, Peter Takacs, Archana Chatterjee, Rhoda S Sperling, Nahida Chakhtoura, Mark M Blatter, Jacob Lalezari, Marie-Pierre David, Lan Lin, Frank Struyf & Gary Dubin. (2014) Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial. Human Vaccines & Immunotherapeutics 10:12, pages 3435-3445.
Read now
Read now
Archana Chatterjee. (2014) The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon. Expert Review of Vaccines 13:11, pages 1279-1290.
Read now
Read now
Paulo S Naud, Cecilia M Roteli-Martins, Newton S De Carvalho, Julio C Teixeira, Paola C de Borba, Nervo Sanchez, Toufik Zahaf, Gregory Catteau, Brecht Geeraerts & Dominique Descamps. (2014) Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine. Human Vaccines & Immunotherapeutics 10:8, pages 2147-2162.
Read now
Read now
Margaret A Stanley, Staci L Sudenga & Anna R Giuliano. (2014) Alternative dosage schedules with HPV virus-like particle vaccines. Expert Review of Vaccines 13:8, pages 1027-1038.
Read now
Read now
Ryo Konno, Hiroyuki Yoshikawa, Marie Okutani, Wim Quint, Pemmaraju V Suryakiran, Lan Lin & Frank Struyf. (2014) Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Human Vaccines & Immunotherapeutics 10:7, pages 1781-1794.
Read now
Read now
Fengcai Zhu, Juan Li, Yuemei Hu, Xiang Zhang, Xiaoping Yang, Hui Zhao, Junzhi Wang, Jianguo Yang, Guodong Xia, Qinyong Dai, Haiwen Tang, Pemmaraju V Suryakiran, Sanjoy K Datta, Dominique Descamps, Dan Bi & Frank Struyf. (2014) Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. Human Vaccines & Immunotherapeutics 10:7, pages 1795-1806.
Read now
Read now
Barbara Romanowski, Tino F Schwarz, Linda M Ferguson, Murdo Ferguson, Klaus Peters, Marc Dionne, Karin Schulze, Brian Ramjattan, Peter Hillemanns, Ulrich Behre, Pemmaraju Suryakiran, Florence Thomas & Frank Struyf. (2014) Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination. Human Vaccines & Immunotherapeutics 10:5, pages 1155-1165.
Read now
Read now
Ami J Munro & Margaret E Cruickshank. (2014) Impact of HPV immunization on the detection of cervical disease. Expert Review of Vaccines 13:4, pages 533-544.
Read now
Read now
Mitchell Tyler, Ebenezer Tumban & Bryce Chackerian. (2014) Second-generation prophylactic HPV vaccines: successes and challenges. Expert Review of Vaccines 13:2, pages 247-255.
Read now
Read now
Maarten J Postma, Tjalke A Westra, Sibilia Quilici & Nathalie Largeron. (2013) Economic evaluation of vaccines: specificities and future challenges illustrated by recent European examples. Expert Review of Vaccines 12:5, pages 555-565.
Read now
Read now
Lesia K Dropulic & Jeffrey I Cohen. (2012) The challenge of developing a herpes simplex virus 2 vaccine. Expert Review of Vaccines 11:12, pages 1429-1440.
Read now
Read now
Barbara Ma, Bharat Maraj, Nam Phuong Tran, Jayne Knoff, Alexander Chen, Ronald D Alvarez, Chien-Fu Hung & T.-C. Wu. (2012) Emerging human papillomavirus vaccines. Expert Opinion on Emerging Drugs 17:4, pages 469-492.
Read now
Read now
Edith MG van Esch, Marij JP Welters, Ekaterina S Jordanova, J Baptist MZ Trimbos, Sjoerd H van der Burg & Mariëtte IE van Poelgeest. (2012) Treatment failure in patients with HPV 16-induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy. Expert Review of Vaccines 11:7, pages 821-840.
Read now
Read now
Anne Szarewski. (2012) Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types. Expert Review of Vaccines 11:6, pages 645-657.
Read now
Read now
Articles from other publishers (134)
Wenjie Qu, Long Sui & Yanyun Li. (2023) Vaccine escape challenges virus prevention: The example of two vaccine‐preventable oncogenic viruses. Journal of Medical Virology 95:11.
Crossref
Crossref
Ralph J. Lellé & Volkmar KüppersRalph J. Lellé & Volkmar Küppers. 2023. Kolposkopie in der Praxis. Kolposkopie in der Praxis
219
231
.
Ralph J. Lellé & Volkmar KüppersRalph J. Lellé & Volkmar Küppers. 2023. Colposcopy. Colposcopy
209
219
.
Dominik Pruski, Małgorzata Łagiedo-Żelazowska, Sonja Millert-Kalińska, Jan Sikora, Robert Jach & Marcin Przybylski. (2022) Immunity after HPV Vaccination in Patients after Sexual Initiation. Vaccines 10:5, pages 728.
Crossref
Crossref
Megumi Kurosawa, Masayuki Sekine, Manako Yamaguchi, Risa Kudo, Sharon J. B. Hanley, Megumi Hara, Sosuke Adachi, Yutaka Ueda, Etsuko Miyagi, Sayaka Ikeda, Asami Yagi & Takayuki Enomoto. (2022) Long‐term effectiveness of HPV vaccination against HPV infection in young Japanese women: Real‐world data. Cancer Science 113:4, pages 1435-1440.
Crossref
Crossref
Francesco Nicoli, Barbara Mantelli, Eleonora Gallerani, Valentina Telatin, Laura Squarzon, Serena Masiero, Riccardo Gavioli, Giorgio Palù, Luisa Barzon & Antonella Caputo. (2022) Effects of the age of vaccination on the humoral responses to a human papillomavirus vaccine. npj Vaccines 7:1.
Crossref
Crossref
Megumi Kurosawa, Masayuki Sekine, Manako Yamaguchi, Risa Kudo, Sharon J. B. Hanley, Megumi Hara, Sosuke Adachi, Yutaka Ueda, Etsuko Miyagi, Sayaka Ikeda, Asami Yagi & Takayuki Enomoto. (2022) Long-Term Effects of Human Papillomavirus Vaccination in Clinical Trials and Real-World Data: A Systematic Review. Vaccines 10:2, pages 256.
Crossref
Crossref
Emilia Gvozdenović, Lucio Malvisi, Elisa Cinconze, Stijn Vansteelandt, Phoebe Nakanwagi, Emmanuel Aris & Dominique Rosillon. (2021) Causal inference concepts applied to three observational studies in the context of vaccine development: from theory to practice. BMC Medical Research Methodology 21:1.
Crossref
Crossref
Colette M. Gnade, Emily K. Hill, Hannah E. Botkin, Alison R. Hefel, Hayley E. Hansen, Kelsey A. Sheets, Sarah L. Mott, Abbey J. Hardy-Fairbanks & Colleen K. Stockdale. (2021) Is the age of cervical cancer diagnosis changing over time?. Journal of Gynecology Obstetrics and Human Reproduction 50:7, pages 102040.
Crossref
Crossref
Courtney Gidengil, Matthew Bidwell Goetz, Sydne Newberry, Margaret Maglione, Owen Hall, Jody Larkin, Aneesa Motala & Susanne Hempel. (2021) Safety of vaccines used for routine immunization in the United States: An updated systematic review and meta-analysis. Vaccine 39:28, pages 3696-3716.
Crossref
Crossref
Darron R. Brown, Elmar A. Joura, Glorian P. Yen, Smita Kothari, Alain Luxembourg, Alfred Saah, Anuj Walia, Gonzalo Perez, Hanane Khoury, Danielle Badgley & Margaret Stanley. (2021) Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence. Vaccine 39:16, pages 2224-2236.
Crossref
Crossref
Barbara J. Kuter, Suzanne M. Garland, Anna R. Giuliano & Margaret A. Stanley. (2021) Current and future vaccine clinical research with the licensed 2-, 4-, and 9-valent VLP HPV vaccines: What's ongoing, what's needed?. Preventive Medicine 144, pages 106321.
Crossref
Crossref
R. Donken, J. Hoes, M. J. Knol, G. S. Ogilvie, S. Dobson, A. J. King, J. Singer, P. J. Woestenberg, J. A. Bogaards, C. J. L. M. Meijer & H. E. de Melker. (2020) Measuring vaccine effectiveness against persistent HPV infections: a comparison of different statistical approaches. BMC Infectious Diseases 20:1.
Crossref
Crossref
Dominique Rosillon, Corinne Willame, Fernanda Tavares Da Silva, Adrienne Guignard, Sophie Caterina, Sarah Welby & Frank Struyf. (2020)
Meta‐analysis of the risk of autoimmune thyroiditis,
Guillain‐Barré
syndrome, and inflammatory bowel disease following vaccination with
AS04
‐adjuvanted human papillomavirus 16/18 vaccine
. Pharmacoepidemiology and Drug Safety 29:9, pages 1159-1167.
Crossref
Crossref
. (2020) Human Papillomavirus Vaccination. Obstetrics & Gynecology 136:2, pages e15-e21.
Crossref
Crossref
Peter Sasieni & Alejandra Castanon. (2020) Evidence of HPV vaccination efficacy comes from more than clinical trials. Vaccine 38:35, pages 5569-5571.
Crossref
Crossref
Helena C Bartels, James Postle, Ailin C Rogers & Donal Brennan. (2020) Prophylactic human papillomavirus vaccination to prevent recurrence of cervical intraepithelial neoplasia: a meta-analysis. International Journal of Gynecologic Cancer 30:6, pages 777-782.
Crossref
Crossref
Ama G. Ampofo, Shirley A. Gyamfuaah, Nancy S. Opoku, Sabina O. Owusu & Mary B. Ibitoye. (2020) A pilot study of a video-based educational intervention and knowledge of cervical cancer among senior high school students in Ghana: A before-after study. Journal of Cancer Policy 24, pages 100220.
Crossref
Crossref
Ralph-Sydney Mboumba Bouassa, Hélène Péré, Camélia Gubavu, Thierry Prazuck, Mohammad-Ali Jenabian, David Veyer, Jean-François Meye, Antoine Touzé & Laurent Bélec. (2020) Serum and cervicovaginal IgG immune responses against α7 and α9 HPV in non-vaccinated women at risk for cervical cancer: Implication for catch-up prophylactic HPV vaccination. PLOS ONE 15:5, pages e0233084.
Crossref
Crossref
Claire P Rees, Petra Brhlikova & Allyson M Pollock. (2020) Will HPV vaccination prevent cervical cancer?. Journal of the Royal Society of Medicine 113:2, pages 64-78.
Crossref
Crossref
Karen Basen-Engquist, Powel Brown, Adriana M. Coletta, Michelle Savage, Karen Colbert Maresso & Ernest Hawk. 2020. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
337
374.e12
.
Fred Zepp & Markus Hufnagel. 2020. Pädiatrie. Pädiatrie
141
179
.
Fred Zepp & Markus Hufnagel. 2020. Pädiatrie. Pädiatrie
1
39
.
Chun-Rong Liu, Hao Liang, Xi Zhang, Chen Pu, Qin Li, Qiao-Ling Li, Fei-Yang Ren & Jing Li. (2019) Effect of an educational intervention on HPV knowledge and attitudes towards HPV and its vaccines among junior middle school students in Chengdu, China. BMC Public Health 19:1.
Crossref
Crossref
Asmaa Gohar, Nourtan F. Abdeltawab, Nahla Shehata & Magdy A. Amin. (2019) Preclinical study of safety and immunogenicity of combined rubella and human papillomavirus vaccines: Towards enhancing vaccination uptake rates in developing countries. Papillomavirus Research 8, pages 100172.
Crossref
Crossref
Jessica D. McDermott & Daniel W. Bowles. (2019) Epidemiology of Head and Neck Squamous Cell Carcinomas: Impact on Staging and Prevention Strategies. Current Treatment Options in Oncology 20:5.
Crossref
Crossref
Jiantai Qiu, Donia Alson, Ta-Hsien Lee, Ching-Chou Tsai, Ting-Wei Yu, Yu-Sing Chen, Ya-Fang Cheng, Chu-Chi Lin & Scott Schuyler. (2019) Effect of Multiple Vaccinations with Tumor Cell-Based Vaccine with Codon-Modified GM-CSF on Tumor Growth in a Mouse Model. Cancers 11:3, pages 368.
Crossref
Crossref
Hanna Artemchuk, Tiina Eriksson, Mario Poljak, Heljä-Marja Surcel, Joakim Dillner, Matti Lehtinen & Helena Faust. (2019) Long-term Antibody Response to Human Papillomavirus Vaccines: Up to 12 Years of Follow-up in the Finnish Maternity Cohort. The Journal of Infectious Diseases 219:4, pages 582-589.
Crossref
Crossref
Steven G. Reed, Darrick Carter, Corey Casper, Malcolm S. Duthie & Christopher B. Fox. (2018) Correlates of GLA family adjuvants’ activities. Seminars in Immunology 39, pages 22-29.
Crossref
Crossref
Devi Puerto, Viviana Reyes, Cristina Lozano, Lina Buitrago, Diego Garcia, Raúl H. Murillo, Nubia Muñoz, Gustavo A. Hernandez, Laura Sanchez, Carolina Wiesner & Alba L. Combita. (2018) Detection and Genotyping of HPV DNA in a Group of Unvaccinated Young Women from Colombia: Baseline Measures Prior to Future Monitoring Program. Cancer Prevention Research 11:9, pages 581-592.
Crossref
Crossref
John Schiller & Doug Lowy. (2018) Explanations for the high potency of HPV prophylactic vaccines. Vaccine 36:32, pages 4768-4773.
Crossref
Crossref
Ligia A. Pinto, Joakim Dillner, Simon Beddows & Elizabeth R. Unger. (2018) Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development. Vaccine 36:32, pages 4792-4799.
Crossref
Crossref
Helen C Johnson, Erin I Lafferty, Rosalind M Eggo, Karly Louie, Kate Soldan, Jo Waller & W John Edmunds. (2018) Effect of HPV vaccination and cervical cancer screening in England by ethnicity: a modelling study. The Lancet Public Health 3:1, pages e44-e51.
Crossref
Crossref
John T. Schiller, Lauri E. Markowitz, Allan Hildesheim & Douglas R. Lowy. 2018. Plotkin's Vaccines. Plotkin's Vaccines
430
455.e10
.
. (2017) Committee Opinion No. 704: Human Papillomavirus Vaccination. Obstetrics & Gynecology 129:6, pages e173-e178.
Crossref
Crossref
Haïtham Mirghani, Alain C. Jung & Carole Fakhry. (2017) Primary, secondary and tertiary prevention of human papillomavirus-driven head and neck cancers. European Journal of Cancer 78, pages 105-115.
Crossref
Crossref
Joseph E. Tota, James Bentley, Jennifer Blake, François Coutlée, Máire A. Duggan, Alex Ferenczy, Eduardo L. Franco, Michael Fung-Kee-Fung, Walter Gotlieb, Marie-Hélène Mayrand, Meg McLachlin, Joan Murphy, Gina Ogilvie & Sam Ratnam. (2017) Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm. Preventive Medicine 98, pages 5-14.
Crossref
Crossref
Paolo Giorgi Rossi, Francesca Carozzi, Antonio Federici, Guglielmo Ronco, Marco Zappa, Silvia Franceschi, Alessandra Barca, Luisa Barzon, Iacopo Baussano, Carla Berliri, Paolo Bonanni, Fausto Boselli, Sara Boveri, Franco Maria Buonaguro, Elena Burroni, Giuseppe Carillo, Elisa Carretta, Francesco Chini, Massimo Confortini, Paolo Dalla Palma, Silvia Declich, Annarosa Del Mistro, Anna Maria Del Sole, Stefano Ferretti, Giovanni Gabutti, Franco Gargiulo, Cristina Giambi, Stefania Iannazzo, Anna Iossa, Miriam Levi, Flavia Lillo, Vincenzo Maccalini, Maria Luisa Mangia, Luciano Mariani, Carlo Naldoni, Cristina Ocello, Eugenio Paci, Antonella Pellegrini, Antonio Perino, Annamaria Pezzarossi, Massimo Pilia, Antonio Placidi, Maria Grazia Pompa, Francesca Russo, Maria Teresa Sandri, Cristina Sani, Aurora Scalisi, Maria Luisa Schiboni, Nereo Segnan, Mario Sideri, Arsenio Spinillo, Gian Luigi Taddei, Maria Lina Tornesello, Francesco Venturelli, Amina Vocaturo & Manuel Zorzi. (2017) Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference. Preventive Medicine 98, pages 21-30.
Crossref
Crossref
Masato Yokomine, Satoko Matsueda, Kouichiro Kawano, Tetsuro Sasada, Akimasa Fukui, Takuto Yamashita, Nobukazu Komatsu, Shigeki Shichijo, Kazuto Tasaki, Ken Matsukuma, Kyogo Itoh, Toshiharu Kamura & Kimio Ushijima. (2017) Enhancement of humoral and cell mediated immune response to HPV16 L1-derived peptides subsequent to vaccination with prophylactic bivalent HPV L1 virus-like particle vaccine in healthy females. Experimental and Therapeutic Medicine 13:4, pages 1500-1505.
Crossref
Crossref
Stina Syrjänen & Jaana Rautava. 2017. HPV Infection in Head and Neck Cancer. HPV Infection in Head and Neck Cancer
257
267
.
Ramya Kollipara, Christopher Downing, Jacqueline Guidry, Michael Lee, Natalia Mendoza, Cesar Arias, Andrew Peranteau & Stephen K. Tyring. 2017. Clinical and Basic Immunodermatology. Clinical and Basic Immunodermatology
289
312
.
Ruchi R. Shah, Kimberly J. Hassett & Luis A. Brito. 2017. Vaccine Adjuvants. Vaccine Adjuvants
1
13
.
Feng-cai Zhu, Shang-Ying Hu, Ying Hong, Yue-Mei Hu, Xun Zhang, Yi-Ju Zhang, Qin-Jing Pan, Wen-Hua Zhang, Fang-Hui Zhao, Cheng-Fu Zhang, Xiaoping Yang, Jia-Xi Yu, Jiahong Zhu, Yejiang Zhu, Feng Chen, Qian Zhang, Hong Wang, Changrong Wang, Jun Bi, Shiyin Xue, Lingling Shen, Yan-Shu Zhang, Yunkun He, Haiwen Tang, Naveen Karkada, Pemmaraju Suryakiran, Dan Bi & Frank Struyf. (2017) Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial. Cancer Medicine 6:1, pages 12-25.
Crossref
Crossref
Mohamed Macki & Ali A. Dabaja. (2016) Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials. Basic and Clinical Andrology 26:1.
Crossref
Crossref
Daron G. Ferris. (2016) Change Suboptimal Tactics and Promote a National Mandatory Human Papillomavirus Vaccination Program. Journal of Lower Genital Tract Disease 20:4, pages 348-351.
Crossref
Crossref
Alba Lucía Cómbita, Tarik Gheit, Paula González, Devi Puerto, Raúl Hernando Murillo, Luisa Montoya, Alex Vorsters, Severien Van Keer, Pierre Van Damme, Massimo Tommasino, Gustavo Hernández-Suárez, Laura Sánchez, Rolando Herrero & Carolina Wiesner. (2016) Comparison between Urine and Cervical Samples for HPV DNA Detection and Typing in Young Women in Colombia. Cancer Prevention Research 9:9, pages 766-771.
Crossref
Crossref
Julia M.L. Brotherton, Mark Jit, Patti E. Gravitt, Marc Brisson, Aimée R. Kreimer, Sara I. Pai, Carole Fakhry, Joseph Monsonego & Silvia Franceschi. (2016) Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines. International Journal of Cancer 139:3, pages 510-517.
Crossref
Crossref
Theresa Guo, David W. Eisele & Carole Fakhry. (2016) The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer. Cancer 122:15, pages 2313-2323.
Crossref
Crossref
Derek B. Allison & Zahra Maleki. (2016) HPV-related head and neck squamous cell carcinoma: An update and review. Journal of the American Society of Cytopathology 5:4, pages 203-215.
Crossref
Crossref
Margaret Stanley. (2016) HPV vaccines: how many doses are needed for protection?. Future Virology 11:4, pages 283-292.
Crossref
Crossref
David Mesher, Elaine Stanford, Joanne White, Jamie Findlow, Rosalind Warrington, Sukamal Das, Richard Pebody, Ray Borrow & Kate Soldan. (2016) HPV Serology Testing Confirms High HPV Immunisation Coverage in England. PLOS ONE 11:3, pages e0150107.
Crossref
Crossref
Akila N. Viswanathan, Don S. Dizon, Lilian T. Gien & Wui-Jin Koh. 2016. Clinical Radiation Oncology. Clinical Radiation Oncology
1173
1202.e6
.
Margaret Stanley. 2016. The Vaccine Book. The Vaccine Book
245
263
.
Anna Melissa Guerrero, Anne Julienne Genuino, Melanie Santillan, Naiyana Praditsitthikorn, Varit Chantarastapornchit, Yot Teerawattananon, Marissa Alejandria & Jean Anne Toral. (2015) A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines. BMC Public Health 15:1.
Crossref
Crossref
Barbara A. Pahud & Kevin A. Ault. (2015) The Expanded Impact of Human Papillomavirus Vaccine. Infectious Disease Clinics of North America 29:4, pages 715-724.
Crossref
Crossref
Julia M. L. Brotherton & Paul J. N. Bloem. (2015) HPV Vaccination: Current Global Status. Current Obstetrics and Gynecology Reports 4:4, pages 220-233.
Crossref
Crossref
Lynette Denny, Rolando Herrero, Carol Levin & Jane J. Kim. 2015. Disease Control Priorities, Third Edition (Volume 3): Cancer. Disease Control Priorities, Third Edition (Volume 3): Cancer
69
84
.
. (2015) Committee Opinion No. 641. Obstetrics & Gynecology 126:3, pages e38-e43.
Crossref
Crossref
Julia ML Brotherton. (2015) HPV prophylactic vaccines: lessons learned from 10 years experience. Future Virology 10:8, pages 999-1009.
Crossref
Crossref
Mohammed Wahiduzzaman, Chandresh Sharma, Bindu Dey, Neerja Bhatla & Neeta Singh. (2015) Development of chimeric candidate vaccine against HPV18: a proof of concept. Immunologic Research 62:2, pages 189-197.
Crossref
Crossref
John T. Schiller & Douglas R. Lowy. (2015) Raising Expectations For Subunit Vaccine. The Journal of Infectious Diseases 211:9, pages 1373-1375.
Crossref
Crossref
Madelief Mollers, Audrey J. King, Mirjam J. Knol, Mirte Scherpenisse, Chris J.L.M. Meijer, Fiona R.M. van der Klis & Hester E. de Melker. (2015) Effectiveness of human papillomavirus vaccine against incident and persistent infections among young girls: Results from a longitudinal Dutch cohort study. Vaccine 33:23, pages 2678-2683.
Crossref
Crossref
Alberta Pasquale, Scott Preiss, Fernanda Silva & Nathalie Garçon. (2015) Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines 3:2, pages 320-343.
Crossref
Crossref
Paula Gonzalez, Allan Hildesheim, Rolando Herrero, Hormuzd Katki, Sholom Wacholder, Carolina Porras, Mahboobeh Safaeian, Silvia Jimenez, Teresa M. Darragh, Bernal Cortes, Brian Befano, Mark Schiffman, Loreto Carvajal, Joel Palefsky, John Schiller, Rebeca Ocampo, John Schussler, Douglas Lowy, Diego Guillen, Mark H. Stoler, Wim Quint, Jorge Morales, Carlos Avila, Ana Cecilia Rodriguez & Aimée R. Kreimer. (2015) Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica. Vaccine 33:18, pages 2141-2151.
Crossref
Crossref
Dianna E Wilkinson & Stephen Inglis. 2005. Encyclopedia of Life Sciences. Encyclopedia of Life Sciences
1
8
.
Yong-Hee Kim. (2015) Current and Next-generation Vaccines against Human Papillomaviruses. Journal of Bacteriology and Virology 45:3, pages 189.
Crossref
Crossref
Simona Di Mario, Vittorio Basevi, Pier Luigi Lopalco, Sara Balduzzi, Roberto D’Amico & Nicola Magrini. (2015) Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV. Journal of Immunology Research 2015, pages 1-13.
Crossref
Crossref
T Schwarz, M Spaczynski, A Kaufmann, J Wysocki, A Gałaj, K Schulze, P Suryakiran, F Thomas & D Descamps. (2014)
Persistence of immune responses to the
HPV
‐16/18
AS
04‐adjuvanted vaccine in women aged 15–55 years and first‐time modelling of antibody responses in mature women: results from an open‐label 6–year follow‐up study
. BJOG: An International Journal of Obstetrics & Gynaecology 122:1, pages 107-118.
Crossref
Crossref
H.-J. Schmitt. 2015. Pädiatrie. Pädiatrie
1
4
.
Fred Zepp, Heinz-Josef Schmitt & Markus Hufnagel. 2015. Pädiatrie. Pädiatrie
1
43
.
Margaret Stanley. 2015. Medicines For Women. Medicines For Women
271
289
.
Lynette J. Menezes, Jamie P. Morano & Leela Mundra. 2015. Global Virology I - Identifying and Investigating Viral Diseases. Global Virology I - Identifying and Investigating Viral Diseases
15
43
.
Abdulaziz AlObaid, Ismail A Al-Badawi, Hanan Al-Kadri, Kusuma Gopala, Walid Kandeil, Wim Quint, Murad Al-Aker & Rodrigo DeAntonio. (2014) Human papillomavirus prevalence and type distribution among women attending routine gynecological examinations in Saudi Arabia. BMC Infectious Diseases 14:1.
Crossref
Crossref
Proscovia B Namujju, Emma Pajunen, Aline Simen-Kapeu, Lea Hedman, Marko Merikukka, Helja-Marja Surcel, Reinhard Kirnbauer, Dan Apter, Jorma Paavonen, Klaus Hedman & Matti Lehtinen. (2014) Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine – a pilot study. BMC Research Notes 7:1.
Crossref
Crossref
Elisabeth Couto, Ingvil Sæterdal, Lene Kristine Juvet & Marianne Klemp. (2014) HPV catch-up vaccination of young women: a systematic review and meta-analysis. BMC Public Health 14:1.
Crossref
Crossref
Robine Hofman, Esther W de Bekker-Grob, Hein Raat, Theo JM Helmerhorst, Marjolein van Ballegooijen & Ida J Korfage. (2014) Parents’ preferences for vaccinating daughters against human papillomavirus in the Netherlands: a discrete choice experiment. BMC Public Health 14:1.
Crossref
Crossref
Khairya Moosa, Adel Salman Alsayyad, Wim Quint, Kusuma Gopala & Rodrigo DeAntonio. (2014) An epidemiological study assessing the prevalence of human papillomavirus types in women in the Kingdom of Bahrain. BMC Cancer 14:1.
Crossref
Crossref
ALIYA A. ALSALEH & ABBA B. GUMEL. (2014) DYNAMICS ANALYSIS OF A VACCINATION MODEL FOR HPV TRANSMISSION. Journal of Biological Systems 22:04, pages 555-599.
Crossref
Crossref
Julia ML Brotherton. (2014) Human papillomavirus vaccination: Where are we now?. Journal of Paediatrics and Child Health 50:12, pages 959-965.
Crossref
Crossref
Tino F. Schwarz, Li-Min Huang, Tzou-Yien Lin, Christoph Wittermann, Falko Panzer, Alejandra Valencia, Pemmaraju V. Suryakiran, Lan Lin & Dominique Descamps. (2014) Long-term Immunogenicity and Safety of the HPV-16/18 AS04-adjuvanted Vaccine in 10- to 14-year-old Girls. Pediatric Infectious Disease Journal 33:12, pages 1255-1261.
Crossref
Crossref
Allyson K. Palmer, Antoneicka L. Harris & Robert M. Jacobson. (2014) Human Papillomavirus Vaccination: A Case Study in Translational Science. Clinical and Translational Science 7:5, pages 420-424.
Crossref
Crossref
D. Scott LaMontagne, Emmanuel Mugisha, Yuanji Pan, Edward Kumakech, Aloysius Ssemaganda, Troy J. Kemp, Jane Cover, Ligia A. Pinto & Mahboobeh Safaeian. (2014) Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda. Vaccine 32:47, pages 6303-6311.
Crossref
Crossref
Thorsten Rieck, Marcel Feig, Yvonne Deleré & Ole Wichmann. (2014) Utilization of administrative data to assess the association of an adolescent health check-up with human papillomavirus vaccine uptake in Germany. Vaccine 32:43, pages 5564-5569.
Crossref
Crossref
Luisa Barzon, Laura Squarzon, Serena Masiero, Monia Pacenti, Giorgia Marcati, Barbara Mantelli, Liliana Gabrielli, Maria Grazia Pascucci, Tiziana Lazzarotto, Antonella Caputo & Giorgio Palù. (2014) Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes. Vaccine 32:41, pages 5357-5362.
Crossref
Crossref
Allan Hildesheim, Sholom Wacholder, Gregory Catteau, Frank Struyf, Gary Dubin & Rolando Herrero. (2014) Efficacy of the HPV-16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 32:39, pages 5087-5097.
Crossref
Crossref
Jianhui Nie, Weijin Huang, Xueling Wu & Youchun Wang. (2014) Optimization and validation of a high throughput method for detecting neutralizing antibodies against human papillomavirus (HPV) based on pseudovirons. Journal of Medical Virology 86:9, pages 1542-1555.
Crossref
Crossref
Robine Hofman, Esther W. de Bekker-Grob, Jan Hendrik Richardus, Harry J. de Koning, Marjolein van Ballegooijen & Ida J. Korfage. (2014) Have Preferences of Girls Changed Almost 3 Years after the Much Debated Start of the HPV Vaccination Program in the Netherlands? A Discrete Choice Experiment. PLoS ONE 9:8, pages e104772.
Crossref
Crossref
Xavier Castellsagué, Paulo Naud, Song-Nan Chow, Cosette M. Wheeler, Maria Julieta V. Germar, Matti Lehtinen, Jorma Paavonen, Unnop Jaisamrarn, Suzanne M. Garland, Jorge Salmerón, Dan Apter, Henry Kitchener, Julio C. Teixeira, S. Rachel Skinner, Genara Limson, Anne Szarewski, Barbara Romanowski, Fred Y. Aoki, Tino F. Schwarz, Willy A. J. Poppe, F. Xavier Bosch, Newton S. de Carvalho, Klaus Peters, Wiebren A. A. Tjalma, Mahboobeh Safaeian, Alice Raillard, Dominique Descamps, Frank Struyf, Gary Dubin, Dominique Rosillon & Laurence Baril. (2014) Risk of Newly Detected Infections and Cervical Abnormalities in Women Seropositive for Naturally Acquired Human Papillomavirus Type 16/18 Antibodies: Analysis of the Control Arm of PATRICIA. The Journal of Infectious Diseases 210:4, pages 517-534.
Crossref
Crossref
Reneé C. Ireton & Michael GaleJr.Jr.. (2014) Pushing to a cure by harnessing innate immunity against hepatitis C virus. Antiviral Research 108, pages 156-164.
Crossref
Crossref
Hanna Seitz & Martin Müller. (2014) Current perspectives on HPV vaccination: a focus on targeting the L2 protein. Future Virology 9:7, pages 633-653.
Crossref
Crossref
Vivien D. Tsu, Tania Cernuschi & D. Scott LaMontagne. (2014) Lessons Learned From HPV Vaccine Delivery in Low-Resource Settings and Opportunities for HIV Prevention, Treatment, and Care Among Adolescents. JAIDS Journal of Acquired Immune Deficiency Syndromes 66:Supplement 2, pages S209-S216.
Crossref
Crossref
Ma?gorzata Wierzbicka, Agata J?zefiak, Joanna Jackowska, Jaros?aw Szyd?owski & Anna Go?dzicka-J?zefiak. (2014) HPV vaccination in head and neck HPV-related pathologies. Otolaryngologia Polska 68:4, pages 157-173.
Crossref
Crossref
Aimée R. Kreimer. (2014) Prospects for prevention of HPV-driven oropharynx cancer. Oral Oncology 50:6, pages 555-559.
Crossref
Crossref
Katherine A. Lyseng-Williamson. (2014) Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine (Cervarix®): A Guide to Its Two-Dose Schedule in Girls Aged 9–14 Years in the EU. Pediatric Drugs 16:3, pages 247-253.
Crossref
Crossref
K Kavanagh, K G J Pollock, A Potts, J Love, K Cuschieri, H Cubie, C Robertson & M Donaghy. (2014) Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. British Journal of Cancer 110:11, pages 2804-2811.
Crossref
Crossref
Hanna Seitz, Elena Canali, Lis Ribeiro-M?ller, Anik? P?lfi, Angelo Bolchi, Massimo Tommasino, Simone Ottonello & Martin M?ller. (2014) A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses. Vaccine 32:22, pages 2610-2617.
Crossref
Crossref
Helen S. Marshall, Claudia Proeve, Joanne Collins, Rebecca Tooher, Maree O’Keefe, Teresa Burgess, S. Rachel Skinner, Maureen Watson, Heather Ashmeade & Annette Braunack-Mayer. (2014) Eliciting youth and adult recommendations through citizens’ juries to improve school based adolescent immunisation programs. Vaccine 32:21, pages 2434-2440.
Crossref
Crossref
Maria‐Genalin Angelo, Marie‐Pierre David, Julia Zima, Laurence Baril, Gary Dubin, Felix Arellano & Frank Struyf. (2014) Pooled analysis of large and long‐term safety data from the human papillomavirus‐16/18‐AS04‐adjuvanted vaccine clinical trial programme. Pharmacoepidemiology and Drug Safety 23:5, pages 466-479.
Crossref
Crossref
Benoît Levast, Sunita Awate, Lorne Babiuk, George Mutwiri, Volker Gerdts & Sylvia van Drunen Littel-van den Hurk. (2014) Vaccine Potentiation by Combination Adjuvants. Vaccines 2:2, pages 297-322.
Crossref
Crossref
Louise Cadman. (2014) Human papillomavirus vaccination and public health. Nurse Prescribing 12:4, pages 180-184.
Crossref
Crossref
Helen Beer, Sam Hibbitts, Sinead Brophy, M.A. Rahman, Jo Waller & Shantini Paranjothy. (2014) Does the HPV vaccination programme have implications for cervical screening programmes in the UK?. Vaccine 32:16, pages 1828-1833.
Crossref
Crossref
Abdulaziz Ahmed Al-Darwish, Abdullah Fouad Al-Naim, Khalid Saleh Al-Mulhim, Nasser Khaled Al-Otaibi, Mohammed Saad Morsi & Ansari Mukhtar Aleem. (2014) Knowledge about Cervical Cancer Early Warning Signs and Symptoms, Risk Factors and Vaccination among Students at a Medical School in Al-Ahsa, Kingdom of Saudi Arabia. Asian Pacific Journal of Cancer Prevention 15:6, pages 2529-2532.
Crossref
Crossref
. (2014) Committee Opinion No. 588. Obstetrics & Gynecology 123:3, pages 712-718.
Crossref
Crossref
Carine Dochez, Johannes J. Bogers, Rita Verhelst & Helen Rees. (2014) HPV vaccines to prevent cervical cancer and genital warts: an update. Vaccine 32:14, pages 1595-1601.
Crossref
Crossref
Lis Ribeiro-Müller & Martin Müller. (2014) Prophylactic papillomavirus vaccines. Clinics in Dermatology 32:2, pages 235-247.
Crossref
Crossref
Kwang Sung Kim, Shin Ae Park, Kyung-Nam Ko, Seokjae YiYang Je Cho. (2014) Current status of human papillomavirus vaccines. Clinical and Experimental Vaccine Research 3:2, pages 168.
Crossref
Crossref
Britt K. Erickson, Emily E. Landers & Warner K. Huh. (2014) Update on Vaccination Clinical Trials for HPV-Related Disease. Clinical Therapeutics 36:1, pages 8-16.
Crossref
Crossref
Fred Zepp, Heinz-Josef Schmitt, Hans Wolfgang Kreth & Markus Hufnagel. 2014. Pädiatrie. Pädiatrie
113
137
.
David Hawkes, Candice E Lea & Matthew J Berryman. (2013) Answering human papillomavirus vaccine concerns; a matter of science and time. Infectious Agents and Cancer 8:1.
Crossref
Crossref
Erich V. Kliewer, Salaheddin M. Mahmud, Alain A. Demers & Pascal Lambert. (2013) Human papillomavirus vaccination and Pap testing profile in Manitoba, Canada. Vaccine 32:1, pages 33-38.
Crossref
Crossref
Eileen F. Dunne & Ina U. Park. (2013) HPV and HPV-Associated Diseases. Infectious Disease Clinics of North America 27:4, pages 765-778.
Crossref
Crossref
F. Kowalzik & F. Zepp. (2013) Aktuelle STIKO-Impfempfehlungen für Kinder und JugendlicheCurrent STIKO vaccination recommendations for children and adolescents. Monatsschrift Kinderheilkunde 161:12, pages 1136-1145.
Crossref
Crossref
Mahboobeh Safaeian, Carolina Porras, Yuanji Pan, Aimee Kreimer, John T. Schiller, Paula Gonzalez, Douglas R. Lowy, Sholom Wacholder, Mark Schiffman, Ana C. Rodriguez, Rolando Herrero, Troy Kemp, Gloriana Shelton, Wim Quint, Leen-Jan van Doorn, Allan Hildesheim & Ligia A. Pinto. (2013) Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial. Cancer Prevention Research 6:11, pages 1242-1250.
Crossref
Crossref
Rosa De Vincenzo, Caterina Ricci, Carmine Conte & Giovanni Scambia. (2013) HPV vaccine cross-protection: Highlights on additional clinical benefit. Gynecologic Oncology 130:3, pages 642-651.
Crossref
Crossref
Ebenezer Tumban, Julianne Peabody, David S. Peabody & Bryce Chackerian. (2013) A universal virus-like particle-based vaccine for human papillomavirus: Longevity of protection and role of endogenous and exogenous adjuvants. Vaccine 31:41, pages 4647-4654.
Crossref
Crossref
Alba Cómbita, Diego Duarte, Josefa Rodríguez, Mónica Molano, Lina Martínez, Pilar Romero, Lina Trujillo, Mauricio González, Joaquín Luna, Natascha Ortiz, Gustavo Hernández, Pierre Coursaget & Antoine Touzé. (2013) Evaluation of the immune response to human papillomavirus types 16, 18, 31, 45 and 58 in a group of Colombian women vaccinated with the quadrivalent vaccine. Revista Colombiana de Cancerología 17:3, pages 103-110.
Crossref
Crossref
Madelief Mollers, Jeanique M. Vossen, Mirte Scherpenisse, Fiona R.M. van der Klis, Chris J.L.M. Meijer & Hester E. de Melker. (2013) Review: Current knowledge on the role of HPV antibodies after natural infection and vaccination: Implications for monitoring an HPV vaccination programme. Journal of Medical Virology 85:8, pages 1379-1385.
Crossref
Crossref
Silvia de Sanjose, Cosette M. Wheeler, Wim G.V. Quint, William C. Hunt, Nancy E. Joste, Laia Alemany, F. Xavier Bosch, Evan R. Myers & Philip E. Castle. (2013) Age-Specific Occurrence of HPV16- and HPV18-Related Cervical Cancer. Cancer Epidemiology, Biomarkers & Prevention 22:7, pages 1313-1318.
Crossref
Crossref
Matti Lehtinen & Joakim Dillner. (2013) Clinical trials of human papillomavirus vaccines and beyond. Nature Reviews Clinical Oncology 10:7, pages 400-410.
Crossref
Crossref
Mélanie Drolet, Marie-Claude Boily, Nicolas Van de Velde, Eduardo L. Franco & Marc Brisson. (2013) Vaccinating Girls and Boys with Different Human Papillomavirus Vaccines: Can It Optimise Population-Level Effectiveness?. PLoS ONE 8:6, pages e67072.
Crossref
Crossref
Papa Salif Sow, Deborah Watson-Jones, Nancy Kiviat, John Changalucha, Khardiata Diallo Mbaye, Joelle Brown, Kouro Bousso, Bazil Kavishe, Aura Andreasen, Macoumba Toure, Saidi Kapiga, Philippe Mayaud, Richard Hayes, Marie Lebacq, Marjan Herazeh, Florence Thomas & Dominique Descamps. (2013) Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10–25-Year-Old HIV-Seronegative African Girls and Young Women. The Journal of Infectious Diseases 207:11, pages 1753-1763.
Crossref
Crossref
J. Horn, O. Damm, M.E.E. Kretzschmar, Y. Deleré, O. Wichmann, A.M. Kaufmann, E. Garbe, A. Krämer, W. Greiner & R.T. Mikolajczyk. (2013) Estimating the long-term effects of HPV vaccination in Germany. Vaccine 31:19, pages 2372-2380.
Crossref
Crossref
Péter Bősze. (2013) The first vaccine against cancer: the human papillomavirus vaccine. Orvosi Hetilap 154:16, pages 603-618.
Crossref
Crossref
CHRISTOPHER J. DARUS & JENNIFER J. MUELLER. (2013) Development and Impact of Human Papillomavirus Vaccines. Clinical Obstetrics and Gynecology 56:1, pages 10-16.
Crossref
Crossref
Xixiu Xie, Yanchun Liu, Ting Zhang, Yanying Xu, Qifeng Bao, Xue Chen, Hongyang Liu & Xuemei Xu. (2012) Human papillomavirus type 58 L1 virus-like particles purified by two-step chromatography elicit high levels of long-lasting neutralizing antibodies. Archives of Virology 158:1, pages 193-199.
Crossref
Crossref
Anne Szarewski. (2012) HPV Vaccination and Cervical Cancer. Current Oncology Reports 14:6, pages 559-567.
Crossref
Crossref
Nicolas Van de Velde, Marie-Claude Boily, M?lanie Drolet, Eduardo L. Franco, Marie-H?l?ne Mayrand, Erich V. Kliewer, Fran?ois Coutl?e, Jean-Fran?ois Laprise, Tal?a Malag?n & Marc Brisson. (2012) Population-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model?Based Analysis. JNCI: Journal of the National Cancer Institute 104:22, pages 1712-1723.
Crossref
Crossref
John T. Schiller, Xavier Castellsagué & Suzanne M. Garland. (2012) A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines. Vaccine 30, pages F123-F138.
Crossref
Crossref
John T. Schiller & Douglas R. Lowy. (2012) Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nature Reviews Microbiology 10:10, pages 681-692.
Crossref
Crossref
Lynette Denny & Rose Anorlu. (2012) Cervical Cancer in Africa. Cancer Epidemiology, Biomarkers & Prevention 21:9, pages 1434-1438.
Crossref
Crossref
Erica R. Heitmann & Diane M. Harper. (2012) Prophylactic HPV Vaccines and Prevention of Cervical Intraepithelial Neoplasia. Current Obstetrics and Gynecology Reports 1:3, pages 95-105.
Crossref
Crossref
Muhieddine Seoud, Wiebren A.A. Tjalma & Veerle Ronsse. (2011) Cervical adenocarcinoma: Moving towards better prevention. Vaccine 29:49, pages 9148-9158.
Crossref
Crossref
Esther W. de Bekker-Grob, Robine Hofman, Bas Donkers, Marjolein van Ballegooijen, Theo J.M. Helmerhorst, Hein Raat & Ida J. Korfage. (2010) Girls’ preferences for HPV vaccination: A discrete choice experiment. Vaccine 28:41, pages 6692-6697.
Crossref
Crossref
Chris T Bauch, Meng Li, Gretchen Chapman & Alison P Galvani. (2010) Adherence to cervical screening in the era of human papillomavirus vaccination: how low is too low?. The Lancet Infectious Diseases 10:2, pages 133-137.
Crossref
Crossref